Clinical Trial Search

Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 25; 22; 19 Participants — p=0.003

Primary: Number of Participants With Premature Ovarian Insufficiency — 10; 38 Participants

Primary: Pregnancy Rate — 2.1 percentage of participants

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059

Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants

Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)

Primary: Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority…

Primary: Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites — 80; 75; 86; 65 % of Treated Sites

Primary: Progression-Free Survival (PFS) — 7.63; 6.83 Months — p== 0.0100

Primary: Seroconversion Rate at Day 11 — 90.4; 93.5 % of participants

Primary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response — 342; 326; 309; 108 Participants — p=<0.0001

Primary: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population — 5.6; 1.7 months — p=<0.0001

Primary: Overall Survival (OS) — 15.2; 16.6 Months — p=0.0940

Primary: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS) — 147; 133 Participants

Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001